Adjuvant Molecular Hydrogen Facilitates Immunosuppressant Tapering and Sustained Remission in Systemic Lupus Erythematosus: A Case Report.
Hong-Jie Lin, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu · In vivo (Athens, Greece) · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
/AIM: Management of systemic lupus erythematosus (SLE) remains challenging: intensive immunosuppression increases infection risk, whereas dose reduction may trigger disease flares, this strategy may represent a promising immunosuppressant-sparing approach and warrants validation in controlled trials. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in BACKGROUND/AIM: Management of systemic lupus erythematosus (SLE) remains challenging: intensive immunosuppression increases infection risk, whereas dose reduction may trigger disease flares. This strategy may represent a promising immunosuppressant-sparing approach and warrants validation in controlled trials.
What the Researchers Studied
The researchers studied BACKGROUND/AIM: Management of systemic lupus erythematosus (SLE) remains challenging: intensive immunosuppression increases infection risk, whereas dose reduction may trigger disease flares. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Molecular hydrogen (H₂), a selective antioxidant with anti-inflammatory properties, may serve as an adjunct therapy, potentially maintaining disease control while reducing immunosuppressive burden. Oral H₂ capsule therapy was initiated as an adjunct. This strategy may represent a promising immunosuppressant-sparing approach and warrants validation in controlled trials.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was BACKGROUND/AIM: Management of systemic lupus erythematosus (SLE) remains challenging: intensive immunosuppression increases infection risk, whereas dose reduction may trigger disease flares.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.